Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
188
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer

Pietro Di Marino1 Clinical Oncology Unit, SS Annunziata Hospital, Chieti, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1330-683X
ORCID Icon,
Cosima Chiapperino1 Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy
,
Francesca Chiara Primavera1 Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy
,
Maria Teresa Martino1 Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy
,
Davide Brocco2 Department of Pharmacy, University G. D’Annunzio, Chieti- Pescara, Italy
,
Consiglia Carella1 Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy
,
Antonino Grassadonia3 Department of Innovative Technologies in Medicine and Dentistry, University G. D’Annunzio, Chieti- Pescara, Italy
,
Nicola Tinari4 Department of Medical, Oral and Biotechnological Sciences, University G. D’Annunzio, Chieti-Pescara, ItalyORCID Iconhttps://orcid.org/0000-0001-8449-5407
ORCID Icon &
Michele De Tursi3 Department of Innovative Technologies in Medicine and Dentistry, University G. D’Annunzio, Chieti- Pescara, ItalyORCID Iconhttps://orcid.org/0000-0002-1411-1946
ORCID Icon show all
Pages 407-410 | Published online: 11 Apr 2022

References

  • Midha A, Deareden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapll). Am J Cancer Res. 2015;5:2892–2911.
  • Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–1061. doi:10.1158/2159-8290.CD-14-0337
  • Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640. doi:10.1056/NEJMoa1612674
  • Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;6:383–390. doi:10.1586/14737140.2016.1162103
  • Ramalingam SS, Vansteenkite J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Eng J Med. 2020;382:41–50. doi:10.1056/NEJMoa1913662
  • Erikson AW, Brastianos P, Das S. Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systemic review and meta-analysis. JAMA Newt Open. 2020;3:e20162017.
  • Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a meta-analysis. Int J Cancer. 2019;145:289–294. doi:10.1002/ijc.32097
  • Kishikawa T, Kasai T, Okada M, et al. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thorac Cancer. 2020;11:935–942. doi:10.1111/1759-7714.13378
  • Mezquita L, Varga A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opin Drug Saf. 2018;17:1239–1248. doi:10.1080/14740338.2018.1549222
  • Okamoto I, Yamamoto Y, Harada T, et al. Severe aplastic anemia during osimertinib therapy in a patient with EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer. J Thorac Oncol. 2017;12:46–47. doi:10.1016/j.jtho.2016.12.023
  • Kim RS, Han J, Yoon JH, et al. Severe aplastic anemia during osimertinib treatment in a non-small cell lung cancer patient harboring EGFR T790M mutation. Hematol Med Oncol. 2018;3:1–3.
  • Sala L, Mancini M, Pastore A, et al. Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: a case report and literature review. Lung Cancer. 2020;142:120–122. doi:10.1016/j.lungcan.2020.02.019
  • March JC. Hematopoietic growth factor in the pathogenesis and for treatment of anaplastic anemia. Semin Hematol. 2000;37:81–90. doi:10.1016/S0037-1963(00)90032-5
  • Young NS, Maciejeewski J, Epstein FH. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365–1372. doi:10.1056/NEJM199705083361906
  • Eide IJZ, Helland A, Ekman S, et al. Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib. J Clin Oncol. 2018;36(no. 15_suppl):e21026–e21026. doi:10.1200/JCO.2018.36.15_suppl.e21026
  • Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med. 2020;383:1711–1723. doi:10.1056/NEJMoa2027071

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.